For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  VIP (10-28)
Cognitivepreclinical

VIP (10-28)

VIP(10-28)
Cognitive
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Cognitive
Evidence grade
D
PubMed records
79
Female-tagged
13
Sex-analysis
0
CAS
—
D
Evidence grade D, Preclinical / animal evidence only across 79 indexed studies. No human trial data. How grades work →
Female evidence: None
VIP (10-28): of 79 PubMed records, 13 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

VIP (10-28) is a fragment of vasoactive intestinal peptide (VIP), a neuropeptide with broad signaling roles across neural, immune, and vascular systems. As a defined fragment, it is used as a tool compound in neuro-immune and receptor research, where a partial sequence can help isolate specific receptor interactions from the full peptide's activity.

In research, VIP-related peptides have been studied for their interactions with the VPAC1 and VPAC2 receptors, cAMP signaling, and roles in vasodilation, immune-modulation, and neuroendocrine pathways in vitro and in preclinical systems. Investigators examining receptor selectivity and signaling have used such fragments as research materials to probe these mechanisms.

VIP (10-28) is supplied for in-vitro and laboratory research only, not for human or veterinary use. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

VIP(10-28) is a fragment of vasoactive intestinal peptide used mainly as a mechanistic probe and VIP antagonist in research, including small human microvascular studies. It is not a therapeutic; there are no efficacy trials and no female-specific outcome data.

Evidence in women

Menstrual cycle
Unstudied
No studies examine menstrual cycle interactions.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data exist.
Hormonal interactions
Unstudied
No data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal data.
Sex differences
Unstudied
Small mechanistic studies did not report sex-stratified outcomes.

Mechanism

A VIP fragment that acts as a partial agonist/antagonist at VIP receptors, used to probe VIP-mediated vasodilation and signaling.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)No established human dose; used as a mechanistic probe/antagonist in research.
Routesintravenous
Female-specific dosingNot established

Contraindications: insufficient data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

vasodilation and flushing (mechanistic, in research settings)

VIP (10-28) reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for VIP (10-28)

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from VIP (10-28)'s research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is VIP (10-28)?

VIP (10-28), also known as VIP(10-28), is a research compound in our cognitive category. VIP(10-28) is a fragment of vasoactive intestinal peptide used mainly as a mechanistic probe and VIP antagonist in research, including small human microvascular studies.

Is VIP (10-28) studied in women?

VIP (10-28): of 79 PubMed records, 13 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this none: no PubMed record for VIP (10-28) is tagged as including female subjects, so its effects in women are effectively unstudied. That blank is the finding, not a safety signal, and we do not fill it with guesses.

Has VIP (10-28) been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data exist. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does VIP (10-28) have, and why?

VIP (10-28) carries evidence grade D. Preclinical / animal evidence only across 79 indexed studies. No human trial data.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for VIP (10-28)?

No. A female-specific dose for VIP (10-28) is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is VIP (10-28) administered in research?

In the published literature, VIP (10-28) is administered via intravenous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for VIP (10-28)?

Effects reported in the research literature include vasodilation and flushing (mechanistic, in research settings). Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should VIP (10-28) be stored and handled?

VIP (10-28) sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy VIP (10-28) for research?

For laboratory research use, VIP (10-28) is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy VIP (10-28) at Aurevena Research
Research-use supplier: VIP (10-28) is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

16109832 · 3025826

Related peptides

Arginine VasopressinA
Arginine Vasopressin: of 12,241 PubMed records, 4,072 are tagged as including female subjects and 100 carry a sex-analysis tag.
BromantaneC
Bromantane: of 62 PubMed records, 16 are tagged as including female subjects and 1 carry a sex-analysis tag.
CerebrolysinB
Cerebrolysin: of 629 PubMed records, 172 are tagged as including female subjects and 0 carry a sex-analysis tag.
DavunetideB
Davunetide: of 102 PubMed records, 24 are tagged as including female subjects and 4 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.